- Home
- TORO vs STTK Comparison
TORO vs STTK Comparison
Compare TORO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- STTK
- Stock Information
- Founded
- TORO 2022
- STTK 2016
- Country
- TORO Cyprus
- STTK United States
- Employees
- TORO N/A
- STTK N/A
- Industry
- TORO Marine Transportation
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- STTK Health Care
- Exchange
- TORO Nasdaq
- STTK Nasdaq
- Market Cap
- TORO 62.4M
- STTK 59.7M
- IPO Year
- TORO N/A
- STTK 2020
- Fundamental
- Price
- TORO $2.67
- STTK $0.94
- Analyst Decision
- TORO
- STTK Hold
- Analyst Count
- TORO 0
- STTK 3
- Target Price
- TORO N/A
- STTK $2.00
- AVG Volume (30 Days)
- TORO 42.7K
- STTK 337.6K
- Earning Date
- TORO 11-12-2024
- STTK 11-14-2024
- Dividend Yield
- TORO N/A
- STTK N/A
- EPS Growth
- TORO N/A
- STTK N/A
- EPS
- TORO 0.99
- STTK N/A
- Revenue
- TORO $80,626,531.00
- STTK $6,435,000.00
- Revenue This Year
- TORO N/A
- STTK $115.09
- Revenue Next Year
- TORO N/A
- STTK N/A
- P/E Ratio
- TORO $0.97
- STTK N/A
- Revenue Growth
- TORO N/A
- STTK 382.75
- 52 Week Low
- TORO $2.50
- STTK $0.99
- 52 Week High
- TORO $6.45
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- TORO 33.33
- STTK 29.62
- Support Level
- TORO $2.50
- STTK $1.14
- Resistance Level
- TORO $2.79
- STTK $1.19
- Average True Range (ATR)
- TORO 0.16
- STTK 0.13
- MACD
- TORO -0.02
- STTK 0.02
- Stochastic Oscillator
- TORO 18.20
- STTK 0.00
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.